Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Apparently Bracco doesn't like competition.
Bracco hits Jubilant with patent complaint on rubidium PET
By Wayne Forrest, AuntMinnie.com staff writer
April 6, 2018 -- Contrast developer Bracco Diagnostics has filed a complaint against radiopharmaceutical firm Jubilant DraxImage and two of its affiliates for alleged patent infringement regarding rubidium-based radiopharmaceuticals for cardiac PET studies.
Bracco filed papers on March 27 with the U.S. International Trade Commission (ITC), asking that the ITC issue an order to stop Jubilant from importing its Ruby-Fill rubidium-82 generators and related products and components.
Bracco is also asking for a cease-and-desist order that would prohibit the sale of Jubilant's Ruby elution system and Ruby-Fill generators that have already been imported, as well as damages and injunctive relief. Jubilant Pharma and Jubiliant Life Sciences are included in the litigation.
Bracco has also filed suit against Jubilant in the U.S. District Court for the District of New Jersey with charges similar to the ITC complaint. Bracco's patents relate to strontium-rubidium radioisotope infusion systems, according to a letter Bracco sent to customers on March 27.
"Bracco welcomes fair competition in the marketplace, but it is imperative that competitors respect the patent rights of others," wrote Bracco Vice President and General Counsel Vito DeBari.
In the letter, DeBari claims that Bracco is the "pioneer" in rubidium-82 generators and has "invested significantly" in the development and advancement of rubidium-82 infusion systems. The company said it intends to protect its investments with the complaint and lawsuit.
In a written response, Jubilant said that it has "carefully reviewed" Bracco's allegations and intends to "vigorously defend" its legal positions.
"We are very confident that ultimately Jubilant DraxImage will be successful in this litigation and do not expect the litigation to affect the continuing availability of Ruby-Fill products in the U.S. or elsewhere," the company added.
The Ruby elution system and the proprietary Ruby consumable accessories are used only with the Ruby-Fill rubidium-82 generator for PET imaging of the myocardium and manufactured only by Jubilant DraxImage, according to the company. Both devices are available throughout the U.S.
Bracco's CardioGen-82 generator produces rubidium chloride for myocardial PET imaging under rest and pharmacological stress in adult patients with suspected or existing coronary artery disease.
The Ruby-Fill generator received clearance from the U.S. Food and Drug Administration (FDA) in September 2016 and was first available in the U.S. in May 2017. The device is also available in Canada and Switzerland.
Bracco had not approached Jubilant DraxImage about its concerns regarding possible patent infringement issues, said Sarah Marquis, director of legal affairs for Jubilant DraxImage.
https://www.auntminnie.com/index.aspx?sec=sup&sub=mol&pag=dis&ItemID=120437
70mev magnet is on at Zevacor's facility.
MIT is owned by Positron and is not trying to force bankruptcy. Though it does appear the Kittens (with the help of O'Brate) are trying to force Positron to give them the metal rb technology. They are no longer a part of MIT. Wondering if they will turn up in an official role at Zevacor before too long.
It's very likely Bracco's "new" customers are only able to become customers because others have dropped Bracco making a few generators available. Since it is such a small number, those "new" customers are still able to get old used equipment.
The .02 is just someone "jacking" with the price. There are higher bids.
The higher bids were ignored completely.
Skipped right over mine for sure. Strange.
Talking smack about the Posi-RX which was Zehner's creation, yet rubbing in the fact that Zehner's cyclotron will be installed this fall. Surprised the cyclotron isn't being berated too. lol
I believe Positron will turn around. That's why I'm invested here. Since there is always a shortage of sr-82, would assume Bracco lost some customers due to facilities going out of business or merging. They are not adding customers in huge numbers and will never be able to until supply has stabilized. And there will always be used equipment for sale. Only when supply stabilizes will facilities be looking to invest in new efficient, reliable equipment. Have to wonder why some people hang out here if they don't like the company.
Zevacor's cyclotron is to produce sr-82.
The sole use for sr-82 is rb-82 generators. The sole use for rb-82 generators is PET imaging. The reason there isn't more PET imaging is because of lack of sr-82, which has not given medical facilities a reason to invest in PET equipment.
The government produces sr-82 because it has not been commercially viable for private companies before now. What has changed? The technology to produce sr-82 in increased quantities of better quality. Who owns the technology?... Positron.
It stands to reason if there is more sr-82 produced, there will be an increase in facilities that will want to use PET equipment, therefore an increase in equipment sales. Who sells PET equipment?... Positron.
Positron will benefit from Zevacor's cyclotron even though they didn't build it.
O'Brate now owns 1,308,535,587 shares. Big buys indeed!
Perhaps it would be helpful if a moderator posted rules for using this site. From what I can see (from The Moderator's Handbook), no message should be deleted unless it is:
Spam
Off Topic
Vulgar
Author requests removal
Violation of privacy
Threat of violence or physical harm
It also says:
If a post does not fit into any of these categories the post must not be removed.
Some posts fall into a "gray" area and are borderline depending upon the way they are read. As inclusion is favored over exclusion, please err or the side of not removing posts if they are not clear violations.
Since the beginning of the year?
Rick and JJ used to moderate. Then just Apples. Now Apples and you. Just an observation.
dcool has become a moderator
I agree it is a game changer.
This technology makes sr production profitable. Even if they don't have a cyclotron, others who do will need to license the technology (DOE, and in the near future Zehner). From the PR:
"The developed technology has significant environmental and economic benefits, as it simplifies the production process while markedly increasing the yield and quality of the Sr-82 product derived from rubidium metal."
It appears the processing of this type of sr differs. The PR does say:
"This improved rubidium metal Sr-82 production process, currently practiced in Russia as well as by a French radioisotope production facility, will be applied to future rubidium metal target processing at Positron's Texas facility."
So Positron could be the only facility in North America capable of processing the sr from the rubidium metal sr-82 production process, unless they choose to allow others to license the processing technology, imo.
But the PR does also pretty much state that they still plan to build their own cyclotron.
Continuous shorting/covering to manipulate price.
It's price manipulation, pure and simple.
The shorting continues. Hope the FBI investigates that.
We have seen Form 4s for CEO's investments. No way he was selling as that needs to be documented also and we have seen nothing. However do remember seeing where his shares were restricted. What I see is a whole lot of flipping has been going on along with shorting and covering. Many had not planned to stay in this for so long and are frustrated. I understand that. But Positron has made good moves. Just a matter of time until that becomes obvious to all.
CEO investing in company shows he believes it is a good investment. Anyone following the company can see the tremendous progress. Careful on that merry-go-round. Violent head spinning can cause brain bleed.
Advance the company $1 million interest free and they will give you discounted shares also. Wasn't that long ago you guys were discussing the money CEO and CFO put into the company. Another thing to remember, PET is now being used to diagnose Alzheimers!
SNMMI: ARMI trial shows benefits of Rb-82 PET for heart disease
By Wayne Forrest, AuntMinnie.com staff writer
June 10, 2014 -- ST. LOUIS - Trial results presented on Monday at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting show that rubidium-82 (Rb-82) PET outperformed thallium-201 (Tl-201) SPECT for diagnosing obstructive coronary artery disease -- all while exposing patients to less radiation.
The Alternative Radiopharmaceutical for Myocardial Imaging (ARMI) multicenter clinical trial found that Rb-82 PET imaging had greater sensitivity and specificity than Tl-201 SPECT in patients with at least 50% stenosis. The results also confirmed that Rb-82 PET achieved its high degree of accuracy with a lower radiation dose.
"Importantly, the total radiation dose for the whole rest and stress rubidium scan is less than 2 mSv, which is five to 10 times less than current SPECT imaging using technetium-99m [Tc-99m] or thallium," said study co-author Dr. Robert deKemp, head imaging physicist with the University of Ottawa Heart Institute.
The ARMI trial is designed to evaluate Rb-82 as a viable alternative to Tc-99m and Tl-201 in myocardial perfusion imaging for coronary artery disease.
Rb-82 dilemma
Rb-82 PET is not often used by cardiac facilities because there is a much larger installed base of SPECT cameras, and SPECT isotopes have a long history of effective use for coronary disease, deKemp told AuntMinnie.com.
PET cameras have been used mainly for oncology imaging with FDG; fewer systems are dedicated to cardiac imaging. Ottawa Heart Institute, for example, has two SPECT scanners for perfusion imaging with Tc-99m and Tl-201 and one PET scanner for Rb-82 imaging. In terms of total volume, about one-third of the facility's 6,000 annual studies are Rb-82 PET and two-thirds are Tc-99m SPECT.
The impetus for the trial began in 2009, when the Canadian Institutes of Health Research (CIHR) sent out a call to investigators to identify alternative isotopes for myocardial perfusion imaging due to the severe shortage of Tc-99m.
The Ottawa Heart Institute's Cardiac PET Center had already developed its rubidium generator technology about 15 years ago and had been manufacturing its own generators in-house. (That technology was licensed to radiopharmaceutical firm Jubilant DraxImage in 2007.) ...read more at
http://www.auntminnie.com/index.aspx?sec=sup&sub=mol&pag=dis&ItemID=107657&wf=6005
Cash and cash equivalents end of period $1,178,000.
"Positron began processing Sr-82 from third party irradiators iThemba Labs, U.S.DOE and Arronax." They are clearly moving forward and $1,744,000 cash on hand is much better than previous year.
Need for Alzheimer's imaging is altogether too clear.
Nordion supplying sr is a good thing.
No one can dispute the fact the industry has been suffering because of sr shortage. But there was no mention of Nordion processing sr or manufacturing generators.
Alzheimer's death numbers have been greatly underestimated according to a study reported on the evening news last night. This is a big step toward getting more funding toward prevention and possibly a cure.
Also worth mentioning, Europe recently approved their first PET Alzheimer's imaging drug. And, as we know, brain imaging should be done with PET because the least amount of radiation dose is important, as in heart imaging (Positron's Attrius). Now if they would just approve an imaging drug for bipolar disorder, this board could benefit in more ways than one.
Bracco didn't provide generators for their customer. Then when the customer was able to work out a deal with another Bracco customer to sublease a generator, both were threatened by Bracco. Wow. That's the way I read the lawsuit article. And if that is the way they treat their customers, a new generator entering the market should be welcomed.
Nice find JJ. Positron seems to be taking the right steps to ensure a quality product.
Issued and outstanding will be 14,525,483 after split. Float will be only 7,680,000.
"Positron is acutely focused on production of Sr-82. Positron possesses certain resources and technical advantages, unique to MIT, which will increase current and future strontium supply. Positron anticipates the cardiac PET market to rebound in Q1 2014, beginning with Bracco's ability to now accept new generator customers, and with accelerated expansion upon market entry of the DraxImage's generator, once FDA approved."
That's from the most recent filing.
"Positron will receive relevant volumes of strontium-82 for qualification and will commence with commercial availability beginning in February 2014. This additional supply will enhance the industry's strontium-82 supply and increase the availability of radiopharmaceuticals to the end user. Positron intends to make this Sr-82 API supply available to all rubidium-82 generator producers in the marketplace."
http://www.positron.com/press/post/positron-and-ithemba-labs-enters-into-radioisotope-supply-agreement
It's clear we are moving forward. Never as fast as we wish, but it is happening.
Came from PR Newswire--means it was a PR. LOL
Positron Appoints Joseph Oliverio As President
Date : 11/14/2013
Source : PR Newswire (US)
CHICAGO, Nov. 14, 2013 /PRNewswire/ -- Positron Corporation (OTCBB:POSC) (the "Company"), a nuclear medicine healthcare company, is pleased to announce the appointment of Joseph G. Oliverio as its President. Mr. Oliverio will direct the Company's cardiac PET mission and oversee Positron's PET technology, radiopharmaceutical partnerships, clinical and technical applications for new customer sales and existing users...
http://ih.advfn.com/p.php?pid=nmona&article=60031930
If you are talking about Conroy moving to a different position, you're right, that wasn't in a PR. Guess they didn't figure it was PR worthy since he is still basically doing the same job with a different title... I'm talking about rollout of PosiRx. If he was still COO, would imagine he would be stretched pretty thin with API-Sr production growing near.
Clearly states he is still with the company, just no longer COO. You are correct in that it says "resigns from the position of COO," but I think your focus is very narrow and thus failing to acknowledge the big picture.... HE IS STILL WITH THE COMPANY.
As I said before, COO and President roles often overlap. Now, as they begin to process API-Sr, appointing Oliverio President is probably a good move. They didn't need both a COO and a President. They didn't have both in the old line-up and they don't have both in the new line-up. I'm not sure how that can be more clear.
Nothing has changed except a shift in the priorities. Conroy was COO while focus was bringing Posi-RX to its completion because he was best suited to get the job done. And he did... it's done. Now he is moving into Business Development role because of his expertise. Company is ready to focus on radioisotope business so Oliverio moves into role of President because he is best suited to get the job done.
I don't see how it can be more clear... this is good!
He didn't resign. Interesting reach that you claim he did. What I am saying is that you and others are trying to make this into something bad and it really isn't. He's still with the company and perhaps "Business Development" best defines his role at present. No one can deny that we certainly need some business to develop! lol
The role of COO and President often overlap and many companies have one or the other instead of both.
Old line-up:
Rooney, Chairman of the Board and CEO
Oliverio, Chief Technical Officer and Executive Director of PET
Kitten, Executive Director of Radioisotopes
Conroy, COO and Executive Director of Sales and Marketing
Conn, CFO
New line-up:
Rooney, Chairman of the Board and CEO
Oliverio, President
Kitten, Executive Director of Radioisotopes
Conroy, Business Development
Conn, CFO
"[Conroy] will focus on current and potential PET business development opportunities and lead PosiRx through its next phase of growth..."
I think that explains in a nutshell what he will be doing at Positron. In May the next generation PosiRx was completed. Apparently its now time to move on from development to the next phase. What could come after development... I'm guessing sales, but that is just a guess. However, I don't believe it means just anything or nothing, as you claim.
http://www.positron.com/management
Learn to read. Said he moves around alot. He was with Covidien in several positions, but only one position for 2 years. I don't know his future plans, just going by his history and a move fits... this move is within the company. Next one might be too. I wouldn't be surprised if it is, and also wouldn't be surprised if it isn't. Would be surprised if he stayed put in the same ol' same ol' for a decade.
Conroy isn't gone and nobody has crystal ball. Who knows, if the SEC thing doesn't go well for Rooney, Conroy could be bumped up to CEO.
LOL The way you guys spin things really is funny.
His history shows 2 years max:
Positron - November 2012 to present
Amerinet - 2 years
Covidien - several positions, most for 1 year but stayed 2 years in one position
Wolters Kluwer - 1 year
Eli Lilly - 2 positions, 2 years in each
No. Moving around is what he does. Check his employment history.
Oliverio's capable of handling the radiopharmaceutical partnerships. That is probably an important factor in this move, imo.
Conroy is still with the company. He just moved to a role of Business Development, which seems to be his area of extpertise. Really don't expect him stay forever though as he tends to move around a lot.
http://www.positron.com/management
Shoulda stayed quiet and let trimmer play his games. It's more fun to sit back and laugh at him. Maybe he'll trivialize the investments so I can continue.
Looks like Rooney is buying.
Also seeing a Form 1N-A and a Form 3.
http://ih.advfn.com/p.php?pid=squote&symbol=posc
Global imaging market could top $49B by 2020
By AuntMinnie.com staff writers
October 22, 2013
The medical imaging device market could exceed $49 billion U.S. (36 billion euros) by 2020, growing at approximately 7% annually.
The forecast comes from a new report by Research and Markets, which estimated the global medical imaging market is worth $30.2 billion (21.9 billion euros) this year and could advance to $32.3 billion (23.5 billion euros) in 2014. Demographics, such as an aging population, is a key factor in market growth, according to the firm.
The report noted a shift from the North American and European markets to the emerging economies of Asia-Pacific, Latin America, and Central and Eastern Europe. For example, the increasing prevalence of cardiovascular diseases has propelled demand for related imaging modalities and software, further underscoring the need for technologically advanced medical imaging technology.
http://www.auntminnie.com/index.aspx?sec=sup&sub=mri&pag=dis&ItemID=105181
Covington Associates to Lead Financing of Cyclotron Project
June 7, 2013
Positron Corporation (OTCBB:POSC), a nuclear medicine healthcare company, announces today that it has retained Covington Associates, LLC (“Covington”), as its investment banking advisor in connection with the financing of its 70 MeV cyclotron project. Covington, a specialty investment banking firm dedicated to healthcare and technology companies, will advise the Company on various financing and strategic opportunities related to the $60 million required for this 70 MeV cyclotron...
http://www.positron.com/press/post/positron-retains-investment-banking-firm-covington-associates-to-lead-finan
Covington is a very reputable firm. They wouldn't have signed on if they couldn't make it happen.
Bobner does use an Attrius. Would assume the show used canned footage of a procedure.
Here is the article about Ochsner Health Systems using Positron's Attrius:
http://www.cardiovascularbusiness.com/topics/imaging/inside-transition-flow-based-patient-care